Leafly

Shop legal, local weed.

Open
advertise on Leafly
DeliveryDispensariesDealsStrainsBrandsProductsCBDDoctorsCannabis 101Social impact

We use cookies for certain features and to improve your experience. See our Cookie Policy  and Privacy Policy to learn more

  • Sign in
  • Create account
  • Strains
  • Shop
  • Delivery
  • Deals
  • Dispensaries
  • CBD Stores
  • Brands
  • Products
  • Learn
  • Cannabis 101
  • News
  • Leafly Learn
  • Science of cannabis
  • Doctors
  • Social impact
  • Lab partners
  • Download the Leafly App
  • Advertise on Leafly
    • Leafly.comUSA flag
    • Leafly.caCanadian flag
    • Leafly.deGerman flag
  • Help
Learn. Shop. Get cannabis.
Where are you from?
Are you 21 or older?

By accessing this site, you accept the Terms of Use and Privacy Policy.

  • News
  • Cannabis 101
  • Growing
  • Strains & products
  • CBD
  • Politics
  • Health
  • Lifestyle
  • Science & tech
  • Industry
  • Reports
  • Canada
  • Podcasts
  • Leafly Lists
Politics

FAQ: What We Know About Jeff Sessions’ DOJ Action Against Legal Cannabis

Ben AdlinPublished on January 4, 2018 · Last updated July 28, 2020
Sen. Jeff Sessions, R-Ala., center, talks with reporters after a meeting with Republican presidential candidate Donald Trump and the Senate Republican Conference, Thursday, July 7, 2016, at the National Republican Senatorial Committee headquarters in Washington. (AP Photo/Alex Brandon)

US Attorney General Jeff Sessions announced Thursday that he is rescinding the Cole memo, an Obama-era Department of Justice guideline that set a policy of federal noninterference with state-legal cannabis. While the move itself doesn’t trigger any immediate legal action, it’s a sign that the federal prosecutors may intend to ramp up legal actions against cannabis businesses in legal states.

We’ve tried to answer a few of the most common questions about what Sessions’ move might mean. Do you have others? Let us know in the comments. We’ll be updating this page as the situation develops.

Does This Mean the End of Legal Cannabis?

No. Take a deep breath. The sky is not falling. Sessions’ action today rescinds a Department of Justice policy guideline, not a law. Essentially, the move tells federal prosecutors across the country that DOJ no longer officially opposes them interfering with legal cannabis.

“I think this is an attempt to suppress the growth of the industry, not to kill us.”

Worrisome? Absolutely. The end of legalization? Let’s not get ahead of ourselves.

In Oakland, Harborside co-founder Steve DeAngelo, who in 2016 successfully fended off a yearslong federal enforcement action, said he sees Sessions’ move as a way to slow what’s been a rapid rollout of legal cannabis. “I don’t think this is a big deal,” he told Leafly. “I think this is an attempt to suppress the growth of the industry, not to kill us. It is more of a delaying tactic than a knife to our throat.”

What Happens Next?

Most likely, nothing will happen immediately. While undoing the Cole memo opens the door to federal interference with state-legal cannabis programs, Sessions’ move itself doesn’t trigger any legal action.

If there is any sort of crackdown, the first actions would likely come from individual US attorneys, who oversee federal prosecutions in their respective jurisdictions. Their offices could file civil or criminal actions against state-legal cannabis businesses (or their landlords) in an effort to shutter the businesses.

Why Is Sessions Doing This?

It’s no secret that the attorney general is opposed to cannabis. He’s derided its use in medical treatment and said that “good people don’t smoke marijuana.” He’s claimed that cannabis could make the national opioid epidemic worse despite evidence that opioid use actually decreases in legal states. But for the past year or so, Sessions has been more talk than action.

Shop highly rated dispensaries near you

Showing you dispensaries near
See all dispensaries
  • Loading...
    Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • See all dispensaries
See all dispensaries

Part of the motivation behind his decision to rescind the Cole memo on Thursday could be to chill cannabis activity in state-legal markets. Sessions has formally criticized programs in adult-use states, yet legalization keeps stubbornly spreading, fueled by broad public support from liberals and conservatives alike. Las Vegas launched legal adult-use sales in July, and California opened adult-use retail stores to significant fanfare on New Year’s Day. Sessions may be trying to steal those states’ thunder.

Are There Other Federal Protections?

For now, yes, but not many. The Rohrabacher–Blumenaur amendment, a provision included in a federal spending bill, currently prevents the Justice Department from spending resources to prosecute state-legal medical marijuana. But the measure doesn’t offer any cover for adult-use cannabis, and it’s only in place until later this month; Congress will need to renew that protection for it to continue. It’s possible, however, that Sessions’ reversal of the Cole memo could actually encourage congressional representatives to take further action to safeguard state-legal cannabis.

What Can Be Done?

After last year, you’re tired of hearing this, but: Call your representatives in Congress! Tell them to support measures that protect states’ rights to regulate cannabis as they see fit. Encourage them to support renewing the Rohrabacher–Blumenauer amendment—and while you’re at it, tell them to expand its protections to adult-use cannabis. While federal legalization remains a controversial issue for many politicians to get behind, there’s significant public support for leaving regulation to the states.

Contact information for members of the Senate and House of Representatives is available online.

Do State Officials Have to Hand Over Licensing Records?

Good question. Names of state-licensed cannabis companies, locations, and principal owners are already matters of public record. See: California’s Cannabis Control Bureau website. Any federal DEA agent can see the information just as easily as you or I can.

Leafly’s Peter Hecht put the question to San Francisco cannabis attorney Matt Kumin. Kumin said the Justice Department can indeed take advantage of public information on cannabis businesses, including licensing information, and can be expected to subpoena state tax and sales records on individual cannabis businesses, which are not public. 

“They may try that,” Kumin said. “You will likely see something like that end up in a court battle—because I don’t think California will cooperate with a subpoena. This is the United States of California vs. the United States of America…I think California is well down the road in opposition to federal policies here.”

Does This Affect Banking?

No, not directly. The US Treasury Department’s 2014 policy guidance on banks and credit unions that do business with cannabis-related companies remains unaffected by today’s Justice Department move, as far as we can tell. That guidance can be found here.

Leafly’s Cannabist Capitalist columnist, Alan Brochstein, reminded us this afternoon that the Financial Crimes Enforcement Network (FinCEN), which issued the guidance to banks, is part of the Treasury Department, not the Justice Department. Jeff Sessions has no say in Treasury policy.

Although the FinCEN guidelines remain in place, today’s move by the Justice Department will undoubtedly cause some financial institutions to take a hard look at their current politics and relationships with cannabis-related companies.

As of July 2017, FinCEN reported that 296 banks and 94 credit unions were providing banking services to marijuana-related businesses:

Shop highly rated dispensaries near you

Showing you dispensaries near
See all dispensaries
  • Loading...
    Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • See all dispensaries
See all dispensaries
cole memoJeff Sessionslaw enforcementlaws
Ben Adlin
Ben Adlin
Ben Adlin is a Seattle-based writer and editor who specializes in cannabis politics and law. He was a news editor for Leafly from 2015-2019. Follow him on Twitter: @badlin
View Ben Adlin's articles

The latest in Politics

Show all
  • Ohio just voted to legalize cannabis. Here’s what happens next image
    Ohio just voted to legalize cannabis. Here’s what happens next
    Max Savage Levenson
  • Consumers will save money if cannabis moves to Schedule III image
    Consumers will save money if cannabis moves to Schedule III
    David Downs
  • Minnesota just legalized cannabis: Here’s what you need to know image
    Minnesota just legalized cannabis: Here’s what you need to know
    Max Savage Levenson
  • Opinion: America, flex your rights to cannabis lounges image
    Opinion: America, flex your rights to cannabis lounges
    Jay Wexler
Show all
Get good reads, local deals, and strain spotlights delivered right to your inbox.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.



Stay In Touch

Receive updates on new products, special offers, and industry news.

Something went wrong, please try again.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.

Leafly mobile app
Get high for less.
Download the Leafly app.
Download Leafly: Marijuana Reviews on the App Store
Download Leafly Marijuana Reviews on Google Play

  • List your store
  • List your CBD store
  • List your brand
  • List your practice
  • Certify your lab
  • Business log in

  • About us
  • Careers
  • Newsroom
  • Investor relations
  • Contact us
  • FAQs
  • Accessibility

  • Los Angeles
  • Seattle
  • Portland
  • San Francisco
  • Toronto
  • Detroit

  • Terms of use
  • Commercial terms of use
  • Privacy policy
  • Do not sell my personal information

* Statements made on this website have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Information provided by this website or this company is not a substitute for individual medical advice.


© 2023 Leafly, LLC
Leafly and the Leafly logo are registered trademarks of Leafly, LLC. All Rights Reserved.